$1.03
-0.01-0.96%
At close: -
$1.05
0.021.93%
After Hours: 5:17 PM EDT
Comments
Loading...
Latest Boundless Bio Stock News | NASDAQ:BOLD | Benzinga
Get the latest news on Boundless Bio stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Boundless Bio performance
Categories: All
Monday, June 02, 2025
Wednesday, May 28, 2025
Friday, May 23, 2025
Friday, May 09, 2025
Tuesday, April 01, 2025
Thursday, March 27, 2025
Friday, December 13, 2024
Thursday, December 12, 2024
Thursday, November 07, 2024
Monday, October 14, 2024
Monday, April 22, 2024
Thursday, April 11, 2024
Monday, April 08, 2024
Thursday, March 28, 2024
Wednesday, March 27, 2024
Sunday, March 24, 2024
Tuesday, January 07, 2020
Friday, December 27, 2019
Thursday, December 12, 2019
Wednesday, December 11, 2019
Tuesday, December 10, 2019
Monday, December 09, 2019
Friday, December 06, 2019
Thursday, December 05, 2019
Wednesday, December 04, 2019
- Stocks That Hit 52-Week Highs On Wednesday
- Benzinga's Top Upgrades, Downgrades For December 4, 2019
- Chardan Capital Downgrades Audentes Therapeutics to Neutral, Announces $60 Price Target
- The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug
- SVB Leerink Downgrades Audentes Therapeutics to Market Perform
- 63 Biggest Movers From Yesterday
Tuesday, December 03, 2019
- Mid-Afternoon Market Update: DarioHealth Jumps On Walmart Distribution Deal; Cara Therapeutics Shares Plummet
- 40 Stocks Moving In Tuesday's Mid-Day Session
- Mid-Day Market Update: Audentes Therapeutics Climbs On Acquisition News; ASLAN Pharmaceuticals Shares Slide
- The Gene Therapy Names Moving On The Audentes Buyout Deal
- PreMarket Prep Recap: Red On The Screen And Looking For More
- Japan's Astellas To Buy Gene Therapy Company Audentes For $3B Cash
- Stocks That Hit 52-Week Highs On Tuesday
- Mid-Morning Market Update: Markets Open Lower; Cleveland-Cliffs To Acquire AK Steel For $3.36/Share
- Benzinga's Top Upgrades, Downgrades For December 3, 2019
- BMO Capital Downgrades Audentes Therapeutics to Market Perform, Raises Price Target to $60
- 10 Biggest Price Target Changes For Tuesday
- The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
